Reviewing resTORbio Inc. (TORC)’s and Anika Therapeutics Inc. (NASDAQ:ANIK)’s results – MS Wkly

Since resTORbio Inc. (NASDAQ:TORC) and Anika Therapeutics Inc. (NASDAQ:ANIK) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the profitability, analyst recommendations, risk, dividends, institutional ownership, earnings and valuation of both companies.

Earnings and Valuation

Table 1 highlights resTORbio Inc. and Anika Therapeutics Inc.s gross revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us resTORbio Inc. and Anika Therapeutics Inc.s return on equity, return on assets and net margins.

Liquidity

31.4 and 31.4 are the respective Current Ratio and a Quick Ratio of resTORbio Inc. Its rival Anika Therapeutics Inc.s Current and Quick Ratios are 18.1 and 16.1 respectively. resTORbio Inc. has a better chance of clearing its pay short and long-term debts than Anika Therapeutics Inc.

Analyst Ratings

The following table delivered below contains the ratings and recommendations for resTORbio Inc. and Anika Therapeutics Inc.

The consensus price target of resTORbio Inc. is $23, with potential upside of 215.93%.

Institutional & Insider Ownership

The shares of both resTORbio Inc. and Anika Therapeutics Inc. are owned by institutional investors at 54.1% and 96.6% respectively. 38.1% are resTORbio Inc.s share held by insiders. Insiders Comparatively, held 0.9% of Anika Therapeutics Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year resTORbio Inc. was less bullish than Anika Therapeutics Inc.

Summary

Anika Therapeutics Inc. beats resTORbio Inc. on 7 of the 12 factors.

resTORbio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. The company's lead drug candidate RTB101 is a selective, orally administered, TORC1 inhibitor, which is being tested in a Phase 2b clinical trial as a first in-class immunotherapy for reducing the incidence of respiratory tract infections in the elderly by enhancing the function of the immune system. It also intends to develop RTB101 for additional aging-related indications, such as heart failure or neurodegenerative diseases. The company was founded in 2016 and is based in Boston, Massachusetts.

Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a woven gauze used as a bone graft wrap; HYALOSS used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The companys dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; INCERT, a HA product used for the prevention of post-surgical spinal adhesions; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Here is the original post:

Reviewing resTORbio Inc. (TORC)'s and Anika Therapeutics Inc. (NASDAQ:ANIK)'s results - MS Wkly